CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
D Serine +1 moredrug
Likely dose
D Serine 60 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00817336
NCT00817336Phase 2Completed
CompareCT.gov

Effect of an NMDA-based Intervention on Biomarker Measures of Cognitive Dysfunction in Schizophrenia

Nathan Kline Institute for Psychiatric Research·interventional·Posted Jan 6, 2009·Updated Aug 2, 2017

In Brief

A Phase 2 clinical trial evaluating D Serine and Placebo for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 16 participants across 1 site.

Detailed Summary

N-methyl-D-aspartate (NMDA)-type glutamate receptors are thought to play a pivotal role in neurocognitive dysfunction associated with schizophrenia. Further, several novel glutamate-based classes of compound are presently in development as potential novel treatments for persistent negative and cognitive symptoms. The study will assess effectiveness of a NMDA-based intervention on biomarkers related to schizophrenia as a mechanism for developing appropriate outcome batteries for future trials of novel compounds.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 6, 2009
Enrollment StartJun 1, 2009
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.5 years ago

Interventions

D Serinedrug

60 mg/kg/day

Placebodrug

oral